利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

312 条记录 (耗时 0.03 秒)

    Human elk a voltage-gated potassium channel subunit
    51.
    发明授权
    Human elk a voltage-gated potassium channel subunit 失效
    人类麋鹿是一个电压门控钾通道亚基

    公开(公告)号：US06413741B1

    公开(公告)日：2002-07-02

    申请号：US09343494

    申请日：1999-06-30

    申请人： Timothy J. Jegla ,  Alan Wickenden

    发明人： Timothy J. Jegla ,  Alan Wickenden

    IPC分类号： C12N1512

    CPC分类号： G01N33/6872 ,  C07H21/04 ,  C07K14/705 ,  G01N2333/70571

    摘要： The invention provides isolated nucleic acid and amino acid sequences of hElk, antibodies to hElk, methods of detecting hElk, methods of screening for voltage-gated potassium channel activators and inhibitors using biologically active hElk, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising hElk.

    摘要翻译： 本发明提供hElk的分离的核酸和氨基酸序列，hElk的抗体，检测hElk的方法，筛选电压门控的钾通道激活剂的方法和使用生物活性的hElk的抑制剂，以及用于筛选激活剂和电压 - 门控钾通道包括hElk。

    Human neuropeptide receptor
    52.
    发明授权
    Human neuropeptide receptor 失效
    人神经肽受体

    公开(公告)号：US06410701B1

    公开(公告)日：2002-06-25

    申请号：US08462509

    申请日：1995-06-05

    申请人： Daniel R. Soppet ,  Yi Li ,  Craig A. Rosen

    发明人： Daniel R. Soppet ,  Yi Li ,  Craig A. Rosen

    IPC分类号： C07H2102

    CPC分类号： C07K14/70571 ,  A61K38/00 ,  C07K16/286 ,  C12N2799/026 ,  C12N2799/027 ,  G01N2333/70571 ,  G01N2333/726 ,  G01N2500/10

    摘要： Human neuropeptide receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the neuropeptide receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the neuropeptide receptor nucleic acid sequences and an altered level of the soluble form of the receptors.

    摘要翻译： 公开了人类神经肽受体多肽和编码这些多肽的DNA（RNA）以及通过重组技术产生此类多肽的方法。 还公开了利用这些多肽来鉴定此类多肽的拮抗剂和激动剂的方法，以及分别在治疗上使用激动剂和拮抗剂治疗与神经肽受体多肽的低表达和过表达相关的病症的方法。 还公开了用于检测神经肽受体核酸序列中的突变和受体的可溶形式的改变水平的诊断方法。

    Human n-methyl-d-aspartate receptor type 1 subunits, DNA encoding same and uses therefor
    53.
    发明授权
    Human n-methyl-d-aspartate receptor type 1 subunits, DNA encoding same and uses therefor 失效
    人类N-甲基-D-天冬氨酸受体1型亚基，编码相同的DNA并用于其中

    公开(公告)号：US6033865A

    公开(公告)日：2000-03-07

    申请号：US480474

    申请日：1995-06-06

    申请人： Lorrie P. Daggett ,  Steven B. Ellis ,  Chen Wang Liaw

    发明人： Lorrie P. Daggett ,  Steven B. Ellis ,  Chen Wang Liaw

    IPC分类号： C12N15/09 ,  A61K38/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/10 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  C12Q1/68 ,  C12R1/91 ,  G01N33/50 ,  G01N33/68 ,  C12N15/10 ,  C07K1/00 ,  G01N33/566

    CPC分类号： G01N33/5008 ,  C07K14/70571 ,  G01N33/502 ,  G01N33/5041 ,  G01N33/5058 ,  G01N33/5091 ,  G01N33/6872 ,  A01K2217/05 ,  A61K38/00 ,  G01N2333/70571

    摘要： In accordance with the present invention, there are provided nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. The NMDA receptor subunits of the invention comprise components of NMDA receptors that have cation-selective channels and bind glutamate and NMDA. In one aspect of the invention, the nucleic acids encode NMDAR1 and NMDAR2 subunits of human NMDA receptors. In a preferred embodiment, the invention nucleic acids encode NMDAR1, NMDAR2A and NMDAR2C subunits of human NMDA receptors. In addition to being useful for the production of NMDA receptor subunit proteins, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. Functional glutamate receptors can be assembled, in accordance with the present invention, from a plurality of one type of NMDA receptor subunit protein (homomeric) or from a mixture of two or more types of subunit proteins (heteromeric). In addition to disclosing novel NMDA receptor protein subunits, the present invention also comprises methods for using such receptor subunits to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function. The invention also comprises methods for determining whether unknown protein(s) are functional as NMDA receptor subunits.

    摘要翻译： 根据本发明，提供了编码人NMDA受体蛋白质亚基的核酸和由此编码的蛋白质。 本发明的NMDA受体亚基包含具有阳离子选择性通道并结合谷氨酸和NMDA的NMDA受体的组分。 在本发明的一个方面，核酸编码人NMDA受体的NMDAR1和NMDAR2亚基。 在优选的实施方案中，本发明核酸编码人NMDA受体的NMDAR1，NMDAR2A和NMDAR2C亚基。 除了可用于产生NMDA受体亚基蛋白之外，这些核酸也可用作探针，因此使得本领域技术人员无需过多的实验来鉴定和分离相关的人受体亚单位。 功能性谷氨酸受体可以根据本发明从多种一种NMDA受体亚基蛋白（同源性）或两种或更多种亚基蛋白（异聚体）的混合物组装。 除了公开新的NMDA受体蛋白质亚基之外，本发明还包括使用这些受体亚基来鉴定和表征影响这些受体功能的化合物的方法，例如激动剂，拮抗剂和谷氨酸受体功能的调节剂。 本发明还包括用于确定未知蛋白质是否用作NMDA受体亚基的方法。

    NMDA RECEPTOR CONSTRUCTS TO DETECT AND ISOLATE NMDAR AUTOANTIBODIES
    58.
    发明公开
    NMDA RECEPTOR CONSTRUCTS TO DETECT AND ISOLATE NMDAR AUTOANTIBODIES 审中-公开

    公开(公告)号：US20230280340A1

    公开(公告)日：2023-09-07

    申请号：US17627077

    申请日：2020-07-02

    申请人： Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

    发明人： Hans-Christian Kornau ,  Harald Prüss ,  Craig Curtis Garner ,  Tanita Frey

    IPC分类号： G01N33/564 ,  C07K14/705

    CPC分类号： G01N33/564 ,  C07K14/70571 ,  G01N2333/70571 ,  G01N2800/24

    摘要： A soluble N-methyl-D-aspartate receptor (NMDAR) protein construct includes one or more NMDAR autoantibody epitopes. The construct includes an extracellular domain (ECD) of the NMDAR subunit GluN1 or a fragment of the subunit and an ECD of at least one of the NMDAR subunits GluN2A, GluN2B, GluN2C or GluN2D, or fragment of these subunits. An in vitro method for the detection of NMDAR autoantibodies in a sample includes providing a sample suspected of including NMDAR autoantibodies, providing the NMDAR protein construct as a capture molecule, contacting the sample with the NMDAR protein construct, thereby binding NMDAR autoantibodies from the sample to the NMDAR protein construct, and determining the presence and optionally the amount of bound NMDAR autoantibodies. The method is applied for the diagnosis, prognosis, disease monitoring, patient stratification and/or therapy monitoring of a medical condition associated with autoantibodies against the NMDAR, preferably anti-NMDAR encephalitis.